secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-03-05T23:59:59+00:00
Accession:  0000950170-25-033507
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics: $306.7M cash runway through YE26; FT819 Phase 1 dose expansion in SLE underway
--------------------------------------------------------------------------------

- Cash, cash equivalents and investments of $306.7M; projected operating runway through year-end 2026.
- Initiated Phase 1 dose expansion of FT819 CAR T in SLE with flu-free conditioning (bendamustine or cyclophosphamide alone).
- First SLE patient treated with FT819 as add-on to maintenance therapy without conditioning; no DLTs, CRS, or ICANS.
- Completed Type D meeting with FDA to allow FT819 expansion into AAV, IIM, SSc; multi-dose and re-treatment permitted.
- Q4 total operating expenses $63.6M, including $14.7M non-cash impairment; revenue $1.9M from Ono collaboration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/0000950170-25-033507-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017025033507/fate-20250305.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-033507

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer